...
search icon
cgen-img

Compugen Share Price

CGEN
NAQ
$1.735
+$0.04
(2.35%)
1D
Industry: Life Sciences Tools & Services Sector: Health Care

Compugen Analyst Forecast

Compugen Share Price Chart

Compugen Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$159.01M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
74.63K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.91
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.13 L
$2.38 H
$1.735

About Compugen, Common Stock

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. more

Industry: Life Sciences Tools & ServicesSector: Health Care

Compugen Stock Returns

Time FrameCGENSectorS&P500
1-Week Return-0.58%0.91%-0.82%
1-Month Return-22.02%1.46%1.28%
3-Month Return4.94%3.33%3.98%
6-Month Return9.68%16.03%6.73%
1-Year Return-25.44%9.1%12.24%
3-Year Return126.67%21.02%72.07%
5-Year Return-86.46%36.15%75.69%
10-Year Return-64.66%138.89%258.38%

Compugen Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue2.00M6.00M7.50M33.46M27.86M[{"date":"2020-12-31","value":5.98,"profit":true},{"date":"2021-12-31","value":17.93,"profit":true},{"date":"2022-12-31","value":22.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":83.28,"profit":true}]
Cost of Revenue60.00K680.00K975.00K2.00M7.93M[{"date":"2020-12-31","value":0.76,"profit":true},{"date":"2021-12-31","value":8.58,"profit":true},{"date":"2022-12-31","value":12.3,"profit":true},{"date":"2023-12-31","value":25.27,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit1.94M5.32M6.53M31.45M19.93M[{"date":"2020-12-31","value":6.17,"profit":true},{"date":"2021-12-31","value":16.91,"profit":true},{"date":"2022-12-31","value":20.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":63.37,"profit":true}]
Gross Margin97.00%88.67%87.00%94.01%71.54%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.41,"profit":true},{"date":"2022-12-31","value":89.69,"profit":true},{"date":"2023-12-31","value":96.92,"profit":true},{"date":"2024-12-31","value":73.75,"profit":true}]
Operating Expenses33.44M40.39M41.90M44.45M34.83M[{"date":"2020-12-31","value":75.23,"profit":true},{"date":"2021-12-31","value":90.88,"profit":true},{"date":"2022-12-31","value":94.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":78.35,"profit":true}]
Operating Income(31.50M)(35.07M)(35.37M)(12.99M)(14.89M)[{"date":"2020-12-31","value":-3149600000,"profit":false},{"date":"2021-12-31","value":-3507400000,"profit":false},{"date":"2022-12-31","value":-3537400000,"profit":false},{"date":"2023-12-31","value":-1299200000,"profit":false},{"date":"2024-12-31","value":-1489100000,"profit":false}]
Total Non-Operating Income/Expense3.52M1.74M3.48M6.42M10.38M[{"date":"2020-12-31","value":33.91,"profit":true},{"date":"2021-12-31","value":16.78,"profit":true},{"date":"2022-12-31","value":33.47,"profit":true},{"date":"2023-12-31","value":61.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(29.70M)(34.20M)(33.64M)(9.78M)(9.71M)[{"date":"2020-12-31","value":-2969800000,"profit":false},{"date":"2021-12-31","value":-3420300000,"profit":false},{"date":"2022-12-31","value":-3363600000,"profit":false},{"date":"2023-12-31","value":-978400000,"profit":false},{"date":"2024-12-31","value":-970900000,"profit":false}]
Income Taxes(2.44M)(1.33M)58.00K8.97M4.52M[{"date":"2020-12-31","value":-27.18,"profit":false},{"date":"2021-12-31","value":-14.83,"profit":false},{"date":"2022-12-31","value":0.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":50.41,"profit":true}]
Income After Taxes(27.26M)(32.87M)(33.69M)(18.75M)(14.23M)[{"date":"2020-12-31","value":-2726000000,"profit":false},{"date":"2021-12-31","value":-3287300000,"profit":false},{"date":"2022-12-31","value":-3369400000,"profit":false},{"date":"2023-12-31","value":-1875400000,"profit":false},{"date":"2024-12-31","value":-1423100000,"profit":false}]
Income From Continuous Operations(29.70M)(34.20M)(33.69M)(18.75M)(14.23M)[{"date":"2020-12-31","value":-2969800000,"profit":false},{"date":"2021-12-31","value":-3420300000,"profit":false},{"date":"2022-12-31","value":-3369400000,"profit":false},{"date":"2023-12-31","value":-1875400000,"profit":false},{"date":"2024-12-31","value":-1423100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(27.26M)(32.87M)(33.69M)(18.75M)(14.23M)[{"date":"2020-12-31","value":-2726000000,"profit":false},{"date":"2021-12-31","value":-3287300000,"profit":false},{"date":"2022-12-31","value":-3369400000,"profit":false},{"date":"2023-12-31","value":-1875400000,"profit":false},{"date":"2024-12-31","value":-1423100000,"profit":false}]
EPS (Diluted)(0.37)(0.40)(0.40)(0.22)(0.16)[{"date":"2020-12-31","value":-37,"profit":false},{"date":"2021-12-31","value":-40,"profit":false},{"date":"2022-12-31","value":-40,"profit":false},{"date":"2023-12-31","value":-22,"profit":false},{"date":"2024-12-31","value":-15.58,"profit":false}]

Compugen Ratios

Compugen Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

CGEN
Cash Ratio 4.24
Current Ratio 4.38

Compugen Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CGEN
ROA (LTM) -18.18%
ROE (LTM) -52.95%

Compugen Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CGEN
Debt Ratio Lower is generally better. Negative is bad. 0.55
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.45

Compugen Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CGEN
Trailing PE NM
Forward PE NM
P/S (TTM) 22.91
P/B 3.49
EV/R 11.02
EV/Ebitda NM
PEG NM

FAQs

What is Compugen share price today?

Compugen (CGEN) share price today is $1.735

Can Indians buy Compugen shares?

Yes, Indians can buy shares of Compugen (CGEN) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CGEN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Compugen be purchased?

Yes, you can purchase fractional shares of Compugen (CGEN) via the Vested app. You can start investing in Compugen (CGEN) with a minimum investment of $1.

How to invest in Compugen shares from India?

You can invest in shares of Compugen (CGEN) via Vested in three simple steps:

  • Click on Sign Up or Invest in CGEN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Compugen shares
What is Compugen 52-week high and low stock price?

The 52-week high price of Compugen (CGEN) is $2.38. The 52-week low price of Compugen (CGEN) is $1.13.

What is Compugen price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Compugen (CGEN) is

What is Compugen price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Compugen (CGEN) is 3.49

What is Compugen dividend yield?

The dividend yield of Compugen (CGEN) is 0.00%

What is the Market Cap of Compugen?

The market capitalization of Compugen (CGEN) is $159.01M

What is Compugen's stock symbol?

The stock symbol (or ticker) of Compugen is CGEN

How Can Investors Use Compugen Share Price Data for Long-Term Investment Decisions?

Consider the share price of Compugen as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Compugen has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Compugen shares for Indian investors?

When investing in Compugen shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Compugen stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Compugen share price with other stocks in the same sector?

Rather than merely checking the share price of Compugen and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Compugen stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top